STOCKS TELEGRAPH

Tag: NASDAQ: ASLN

  • Hot Stocks to Watch Today for Massive End Week Gains

    Hot Stocks to Watch Today for Massive End Week Gains

    The stocks are up after several days of losses and there are stocks that are already outperforming the market in early morning trading. Some of the stocks leading the day’s upside momentum are as below:

    Flexible Solutions International, Inc [NYSE: FSI]

    Flexible Solutions International, Inc today announced year over year increase in revenue for the third quarter of the fiscal year 2020. The company is a leading manufacturer of detergent ingredients, polymers for oil extraction, and water treatment solutions. It also manufactures environmentally safe and biodegradable energy and water conservation technologies.

    In over just one year, sales revenue increased by 10%, from $7.4 million in Q3, 2019, to $8.11 million in Q3, 2020. Dan O’Brien, the Chief Executive Officer welcomed this growth saying that the company is pleased and is gearing to keep that momentum throughout the rest of the year.

    FSI will present its year-end financial results on November 13, 2020, after the market close. It will have a conference call on November 16, 2020, for this purpose.

    MMTEC Inc [NASDAQ: MTC]

    MMTEC, a Chinese technology company that gives access to the U.S. financial markets announced today its financial results for the six months ending June 30, 2020. The company has seen tremendous growth in the six months following the merging of MMBD Trading Limited, and MM Global Securities, Inc., as part of the company. Revenues grew from $177,543 to $329,070, an 85.35%. The revenue has largely been due to commission fees accrued brokerage services. The company’s gross profit saw a significant increase of 189.27% to about $322,044 from $111,328 in 2019 for the same period. Operational loss reduced from $1,308,583 to $1,041,361 in the six months as a result of an increase in revenue, and a subsequent decrease in administration, payroll, and marketing costs.

    ASLAN Pharmaceuticals Ltd [NASDAQ: ASLN]

    Clinical-stage and biopharmaceuticals company ASLAN Pharmaceuticals, announced today its plans to develop ASLAN003 as its next-generation oral inhibitor of DHODH (dihydroorotate dehydrogenase) for autoimmune diseases like multiple sclerosis.The company says that the medication will have 30 times more potency as compared to teriflunomide. The medication is highly selective and a strong inhibitor of the DHODH enzyme in both cell-based and cell-free assays. It is highly effective in pre-clinical studies done on animal models as well as showing promise in terms of safety and efficacy. The company considers it the most viable candidate for the next clinical-trials in the treatment of the mentioned condition.

  • ASLAN Pharmaceuticals (NASDAQ: ASLN) Starts ASLAN004 Atopic Dermatitis Study

    ASLAN Pharmaceuticals (NASDAQ: ASLN) Starts ASLAN004 Atopic Dermatitis Study

    ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) has commenced the multiple ascending dose (MAD) study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis (AD) patients. The company has also opened clinical sites in the US and Australia and also starting enrolling patients. The patients will now enroll from 3 sites in the US, 4 sites in Australia, and 2 existing sites in Singapore.

    ASLAN004 is a first-in-class monoclonal antibody that combines with the IL-13 receptor α1 subunit (IL-13Rα1). It also blocked the signaling of two pro-inflammatory cytokines, IL-4 and IL-13. These cytokines are central to activate symptoms of AD, such as redness and itching of the skin.

    ASLAN Pharmaceuticals has recently started the enrollment in the second cohort of double-blind, placebo-controlled studies in Singapore after the government has lifted the coronavirus restrictions. All 8 patients have been enrolled in the cohort and the company is planning to start enrollment into the third cohort after approval by the Data Monitoring Committee.

    Furthermore, 8 patients will be enrolled in Singapore, the US, and Australia. ASLAN expects to report interim, unblinded data from all 3 dose cohorts in 4Q 2020.

    ASLAN Pharmaceuticals, Inc. (NASDAQ: ASLN) shares were trading up 15.71% at $1.92 at the time of writing on Wednesday.

    ASLAN Pharmaceuticals, Inc. share price went from a low point around $0.35 to briefly over $8.18 in the past 52 weeks, though shares have since pulled back to $1.92. ASLAN market cap has remained high, hitting 72.40 Million at the time of writing.

    The company has earlier participated in H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020.